🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Sponsor trial record
Trackers Companies Trial finder
Sponsor · clinical trials

Genrix (Shanghai) Biopharmaceutical clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our China register with Genrix (Shanghai) Biopharmaceutical as lead sponsor. Synced 26 Sep 2026
14Current trials
6Recruiting now
7Drugs in these trials
1Trial register
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from ClinicalTrials.gov and CTIS registry records · Last verified · Editorial standards
At a glance

Genrix (Shanghai) Biopharmaceutical is the lead sponsor of 14 current clinical trials in our China register. 6 are recruiting patients now. The most common phase is Phase 3. The drugs named most often in its trials are GR1802, Velinotamig specified on specified days and GR2301. The most-studied condition is Multiple Myeloma.

ClinicalTrials.gov trials by status

  • Recruiting643%
  • Not yet open429%
  • Active, closed429%

Trials by phase

  • Phase 3536%
  • Phase 2321%
  • Phase 1321%
  • Phase 1/2321%
01

Clinical trials sponsored by Genrix (Shanghai) Biopharmaceutical

14 on ClinicalTrials.gov
StudyPhaseStatusStartRegisters
A Study of GR1803 Injection Versus Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Participants With Relapsed or Refractory Multiple Myeloma
NCT07452198 · ClinicalTrials.gov ↗ · Multiple Myeloma
Phase 3 Recruiting 2026-03 China
A Phase III Clinical Trail to Evaluate the Efficacy, Safety, Pharmacokinetics and Immunogenicity Characteristics of GR2001 Injection
NCT06635798 · ClinicalTrials.gov ↗ · Tetanus
Drug: HTIG
Phase 3 Recruiting 2024-09 China
A Study of GR1803 in Systemic Lupus Erythematosus
NCT07348055 · ClinicalTrials.gov ↗ · Systemic Lupus Erthematosus, Auto Immune Disease
Phase 1/2 Recruiting 2026-02 China
A Study of IL4Rα Monoclonal Antibody in Patients With Seasonal Allergic Rhinitis
NCT07154342 · ClinicalTrials.gov ↗ · Allergic Rhinitis, Seasonal
Drug: GR1802
Phase 3 Recruiting 2025-08 China
GR1803 Injection in Patients With RRMM
NCT06952075 · ClinicalTrials.gov ↗ · Multiple Myleoma
Phase 2 Recruiting 2025-04 China
A Study to Evaluate the Safety, Immunogenicity, and Pharmacokinetics of GR2303 in Healthy Adult
NCT07199270 · ClinicalTrials.gov ↗ · Health Adult Subjects
Phase 1 Recruiting 2025-09 China
A Clinical Trial of Multiple Doses of GR2301 Injection in Healthy Adult Trial Participants in China.
NCT07647224 · ClinicalTrials.gov ↗ · Multiple Dose, Healthy Adult Participants
Drug: GR2301
Phase 1 Not yet open 2026-06 China
A Study of GR1802 Injection in Patients With Seasonal Allergic Rhinitis.
NCT07199257 · ClinicalTrials.gov ↗ · Allergic Rhinitis, Seasonal
Drug: GR1802
Phase 3 Not yet open 2025-09 China
A Study to Evaluate the Safety of GR2301 Injection in Healthy Volunteers.
NCT07190716 · ClinicalTrials.gov ↗ · Single Ascending Dose, Healthy Subjects
Drug: GR2301
Phase 1 Not yet open 2025-10 China
A Study of GR1803 Injection in Combination With Anti-CD38 Monoclonal Antibody for the Treatment of Participants With Multiple Myeloma
NCT07090954 · ClinicalTrials.gov ↗ · Multiple Myeloma
Phase 1/2 Not yet open 2025-08 China
GR1803 Injection in Patients With Relapsed/Refractory Multiple Myeloma
NCT06566547 · ClinicalTrials.gov ↗ · Multiple Myeloma
Phase 2 Active, closed 2024-08 China
A Study of IL4Rα Monoclonal Antibody in Patients With Seasonal Allergic Rhinitis(SAR).
NCT06315426 · ClinicalTrials.gov ↗ · Allergic Rhinitis
Drug: GR1802
Phase 2 Active, closed 2024-03 China
A Study of GR1802 in Participants With Chronic Sinusitis With Nasal Polyps
NCT06516302 · ClinicalTrials.gov ↗ · Chronic Rhinosinusitis With Nasal Polyps
Drug: GR1802
Phase 3 Active, closed 2024-09 China
Clinical Study to Investigate the Safety, Tolerability, and Pharmacokinetics of GR1603 in SLE
NCT06015230 · ClinicalTrials.gov ↗ · Lupus Erythematosus, Systemic
Phase 1/2 Active, closed 2022-03 China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

02

Drugs in Genrix (Shanghai) Biopharmaceutical trials

7 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

03

Conditions in Genrix (Shanghai) Biopharmaceutical trials

14 conditions
Multiple Myeloma3Allergic Rhinitis, Seasonal2Multiple Dose1Healthy Adult Participants1Tetanus1Systemic Lupus Erthematosus1Auto Immune Disease1Allergic Rhinitis1Single Ascending Dose1Healthy Subjects1Multiple Myleoma1Chronic Rhinosinusitis With Nasal Polyps1Lupus Erythematosus, Systemic1Health Adult Subjects1
04

By trial register

RegisterTrialsRecruiting
Clinical trials in China146

A trial with sites in more than one country appears in each of those registers.

05

Other sponsors in Multiple Myeloma

SponsorTrials
Janssen Research & Development24
AbbVie13
GlaxoSmithKline13
Pfizer8
Celgene5
Zhujiang Hospital4
Regeneron Pharmaceuticals3
European Myeloma Network3
Nanjing IASO Biotechnology3
Xuzhou Medical University3

Sponsors with the most current trials registered for this condition.

06

Questions about Genrix (Shanghai) Biopharmaceutical trials

How many clinical trials does Genrix (Shanghai) Biopharmaceutical sponsor?

Genrix (Shanghai) Biopharmaceutical is the lead sponsor of 14 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Genrix (Shanghai) Biopharmaceutical trials recruiting?

Yes. 6 of its 14 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Genrix (Shanghai) Biopharmaceutical testing?

Its current trials name 7 drugs and biologicals as interventions. The most frequent are GR1802 (4), Velinotamig specified on specified days (4), GR2301 (2), Daratumumab (1) and Dexamethasone (1). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.